In 2005, the WHO-European Organization for Research and Treatment of Cancer identified the disease as a CD4+/CD56+ hematodermic neoplasm due to its derivation from a plasmacytoid dendritic cell precursor (4). This evidence concerns the gene NCAM1 and cancer.